<DOC>
	<DOCNO>NCT01159418</DOCNO>
	<brief_summary>The purpose study determine Maximum Tolerated Dose ( MTD ) Panobinostat ( LBH589 ) administer combination Carboplatin Paclitaxel patient advance solid malignancy identify Recommended Dose ( RD ) subsequent Phase II study .</brief_summary>
	<brief_title>LBH589 Oral Combination With Carboplatin Paclitaxel Advanced Solid Tumors</brief_title>
	<detailed_description>The combination Carboplatin ( C ) Paclitaxel ( PTX ) consider standard treatment patient epithelial ovarian cancer endometrial cancer , USA anthracyclines recommend . In cervical cancer , often renal function impair , C represent convenient substitute cisplatin combination PTX ; NSCLC C PTX regimen first choice therapy outpatient treatment first second line . LBH histone deacetylase ( HDAC ) inhibitor available also oral administration . In combination platinum agent LBH589 could improve efficacy DNA multiple non-exclusive mechanism ( increase drug access chromosomal DNA , interfere DNA repair , modulating level pro antiapoptotic gene proliferation/survival gene ) . The inclusion Paclitaxel combination LBH589 Carboplatin support result already available combination HDAC inhibitor Vorinostat ( suberoylanilide hydroxamic acid ) give orally carboplatin ( AUC 6 mg/ml.h ) paclitaxel ( 200 mg/m2 ) Phase I study patient solid tumor . The regimen prove feasible , well tolerate associate promising antitumor activity patient NSCLC . The mechanism action , preliminary preclinical data , suggest combination LBH589 , Carboplatin Paclitaxel could feasible worthy clinical investigation .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Histological/cytological diagnosis solid tumor treatment Carboplatin Paclitaxel indicate , e.g . NSCLC , GY tumor , prostate cancer , unknown primary 2 . Progressive disease ( also term tumor marker , like CA 125 ovary PSA prostate ) . 3 . Age 1875 year 4 . Prior chemotherapy ≤ 1 line advance disease 5 . ECOG Performance Status &lt; 2 6 . Life expectancy least 3 month 7 . The patient must able read , understand provide write evidence inform consent 8 . Female patient may pregnant lactate must willing practice contraception . The effect LBH589 develop human fetus unknown . For reason , woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry duration study participation . 9 . Male patient surgically sterile must practice medically acceptable contraceptive regimen study treatment 10 . Adequate organ function define follow : ANC &gt; 1500/µL Platelets ≥ 100,000/µL Haemoglobin ≥ 10 g/dl Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 60 ml/min Magnesium , potassium phosphorus ≥ low limit normal correctable supplement Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤ 2.5 x ULN ≤ 5.0 x ULN hepatic involvement present Serum bilirubin ≤ 1.5 x ULN Alkaline phosphatase ( ALP ) ≤ 2.5 x ULN ALP &gt; 2.5 x UNL liver fraction ≤ 2.5 x ULN 1 . Other chemotherapy treatment &lt; 4 week prior enrolment 2 . Hypersensitivity allergic reaction platinum compound Carboplatin® ; hypersensitivity allergic reaction Paclitaxel 3 . Radiotherapy involve &gt; 30 % active bone marrow 4 . Radiotherapy &lt; 4 week prior enrolment 5 . Preexisting peripheral neuropathy ≥ grade 2 6 . Preexisting CTCAE hearing loss tinnitus ≥ grade 2 7 . Symptomatic pleural effusion 8 . Clinically significant third space fluid accumulation ( e.g . ascites , .. ) 9 . Symptomatic brain metastasis meningeal tumor 10 . Patients recover ( &gt; grade 1 ) follow toxicity previous regimen enrolment : fatigue , mucositis , nausea/vomiting , diarrhea 11 . Concurrent enrolment , previous enrolment within 30 day prior registration another investigational device drug trial ( ) receive investigational agent ( ) 12 . Human immunodeficiency virus ( HIV ) infection 13 . History bone marrow major organ transplant 14 . Prior high dose treatment PBSC support 15 . Impaired cardiac function , include one following : Complete Left Bundle Branch Block obligate use cardiac pacemaker congenital long QT syndrome history presence atrial ventricular tachyarrhythmias clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTcF &gt; 480 msec screen ECG Right Bundle Branch block + leave anterior hemiblock ( bifascicular block ) Angina pectoris acute MI ≤ 3 month prior start study drug Other clinically significant heart disease ( e.g . congestive heart failure , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) 16 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , malabsorption syndrome , small bowel resection ) 17 . Acute chronic liver renal disease 18 . Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes , active uncontrolled infection , chronic obstructive chronic restrictive pulmonary disease ) could cause unacceptable safety risk compromise compliance protocol 19 . Concomitant use CYP3A4/5 inhibitor inducer treatment discontinue switched different medication prior start study drug ( medication list Appendix 3 ) . The medication list Appendix 3 relative risk prolong QT interval induce Torsades de Pointes , represent exclusion criterion 20 . Treatment hematopoietic colonystimulating growth factor ( e.g. , GCSF , GMCSF ) ≤ 2 week prior start study drug . 21 . Treatment therapeutic dos sodium warfarin ( Coumarin ) . Low dos Coumarin ( e.g. , ≤ 2 mg/day ) line patency allowable 22 . Patients receive biologic therapy ( exclude antiangiogenics ) immunotherapy ≤ 2 week prior start study treatment recover side effect therapy 23 . Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy 24 . Unable unwilling comply study procedures 25 . Current history alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>histone deacetylase inhibitor</keyword>
</DOC>